ZIOPHARM Oncology Inc (ZIOP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZIOP Stock Price Chart Interactive Chart >
ZIOP Price/Volume Stats
|Current price||$0.87||52-week high||$5.95|
|Prev. close||$0.87||52-week low||$0.77|
|Day high||$0.97||Avg. volume||2,008,312|
|50-day MA||$1.17||Dividend yield||N/A|
|200-day MA||$2.04||Market Cap||187.12M|
ZIOPHARM Oncology Inc (ZIOP) Company Bio
Ziopharm Oncology is a biotechnology corporation employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell-based therapies for the treatment of cancer. The company was founded in 2003 and is based in Boston, Massachusetts.
Most Popular Stories View All
ZIOP Latest News Stream
|Loading, please wait...|
ZIOP Latest Social Stream
View Full ZIOP Social Stream
Latest ZIOP News From Around the Web
Below are the latest news stories about Ziopharm Oncology Inc that investors may wish to consider to help them evaluate ZIOP as an investment opportunity.
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed
Investment company Allred Capital Management, LLC (Current Portfolio) buys Tractor Supply Co, Equifax Inc, NextEra Energy Inc, Newmont Corp, Paychex Inc, sells iShares S&P 500 Growth ETF, Vanguard Total Bond Market ETF, Ford Motor Co, Adobe Inc, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Allred Capital Management, LLC.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
The clinical-stage biopharmaceutical company is examining non-viral T-cell receptor therapies (TCR-T) to fight cancer. There are two reasons for Ziopharm's climb. First, it's a reaction to hitting its 52-week low as investors saw a potential bargain.
Equities analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ZIOPHARM Oncologys earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.11). ZIOPHARM Oncology reported earnings of ($0.11) per share during the same 
ZIOP Price Returns